Artificial intelligence is transforming businesses, with a focus on drug development. Recursion Pharmaceuticals aims to leverage AI for better productivity in finding successful drugs. Analysts see potential, predicting a 53% stock price increase to $7.25 over the next year. However, the company’s $2.1 billion market cap raises concerns for investors.

Recursion’s lead drug candidate, REC-617, is in its first clinical trial. If successful, it could be a groundbreaking cancer treatment. But the reality is that most early-stage cancer drugs don’t make it to market. Investors should proceed with caution and monitor the company’s progress from a distance.

While Recursion Pharmaceuticals shows promise, the Motley Fool Stock Advisor team does not include it in their top 10 stock picks. Past stock recommendations like Netflix and Nvidia have yielded massive returns, showcasing the potential for significant growth. Investors should consider all factors before investing in Recursion Pharmaceuticals.

Read more at Yahoo Finance: The Biotech Stock That’s Too Risky for Most Investors